相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Approaches to Investigating the Protein Interactome of PTEN
Sarah L. Smith et al.
JOURNAL OF PROTEOME RESEARCH (2021)
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
H. Gogas et al.
ANNALS OF ONCOLOGY (2021)
New perspectives on targeting RAF, MEK and ERK in melanoma
Nicolas Dumaz et al.
CURRENT OPINION IN ONCOLOGY (2021)
Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma
Kei Mukai et al.
JOURNAL OF DERMATOLOGY (2021)
BRAF Gene and Melanoma: Back to the Future
Margaret Ottaviano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance
Ewelina Dratkiewicz et al.
CELLS (2021)
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy-Implications for Translational Research
Hrishi Varayathu et al.
FRONTIERS IN ONCOLOGY (2021)
RAF kinases are stabilized and required for dendritic cell differentiation and function
Kristina Riegel et al.
CELL DEATH AND DIFFERENTIATION (2020)
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma
Julie Delyon et al.
CURRENT OPINION IN ONCOLOGY (2020)
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A. Ascierto et al.
EUROPEAN JOURNAL OF CANCER (2020)
Current Advances in the Treatment of BRAF-Mutant Melanoma
Hima Patel et al.
CANCERS (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
L. Ny et al.
ACTA ONCOLOGICA (2020)
The non-linearity of RAF-MEK signaling in dendritic cells
Kristina Riegel et al.
CELL CYCLE (2020)
Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care
Sima Singh et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
Ilaria Proietti et al.
CANCERS (2020)
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
Minjeong Yeon et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer et al.
NATURE MEDICINE (2020)
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
Franz J. Hilke et al.
CANCERS (2020)
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas et al.
NATURE COMMUNICATIONS (2020)
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Magdalena Smiech et al.
GENES (2020)
In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants
Barbara Hernando et al.
PIGMENT CELL & MELANOMA RESEARCH (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
Kristy Kummerow Broman et al.
EXPERT OPINION ON DRUG SAFETY (2019)
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
Hyejin Choi et al.
CELL REPORTS (2019)
Update on Current Treatment Recommendations for Primary Cutaneous Melanoma
Jessica Dowling et al.
DERMATOLOGIC CLINICS (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
Diverging inflammasome signals in tumorigenesis and potential targeting
Rajendra Karki et al.
NATURE REVIEWS CANCER (2019)
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
Liang Cheng et al.
MODERN PATHOLOGY (2018)
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Tamer B. Shabaneh et al.
CANCER RESEARCH (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells
Eva Hajek et al.
Oncotarget (2018)
Immunological effects of BRAF plus MEK inhibition
Paolo A. Ascierto et al.
ONCOIMMUNOLOGY (2018)
Interleukin-1 Beta-A Friend or Foe in Malignancies?
Rebekka Bent et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Marvin Kuske et al.
PHARMACOLOGICAL RESEARCH (2018)
The role of targeted therapy for melanoma in the immunotherapy era
Ryan J. Sullivan
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2018)
Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes
Kyuryung Kim et al.
CANCERS (2018)
Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation
Mario Mandala et al.
LABORATORY INVESTIGATION (2017)
Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma
Winnie S. Liang et al.
GENOME RESEARCH (2017)
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
Helen L. Young et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
The NF1 gene in tumor syndromes and melanoma
Maija Kiuru et al.
LABORATORY INVESTIGATION (2017)
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas
Hezhe Lu et al.
NATURE (2017)
NRAS-mutant melanoma: current challenges and future prospect
Eva Munoz-Couselo et al.
ONCOTARGETS AND THERAPY (2017)
RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
Ting Jin et al.
NATURE COMMUNICATIONS (2017)
Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis
Ling Peng et al.
ONCOTARGET (2017)
Functional expression of Programmed Death-Ligand 1 (B7-H1) by immune Cells and Tumor Cells
Rachel M. Gibbons Johnson et al.
FRONTIERS IN IMMUNOLOGY (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
Overcoming resistance to BRAF inhibitors
Imanol Arozarena et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Immunotherapy in melanoma: Recent advances and future directions
C. Franklin et al.
EJSO (2017)
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
R. Mandal et al.
ONCOGENE (2016)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations
Lavinia Spain et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
Simona Caporali et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
Jurjen Tel et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells
Chery A. Whipple et al.
MELANOMA RESEARCH (2016)
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano et al.
ANNALS OF TRANSLATIONAL MEDICINE (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
Eishu Hirata et al.
CANCER CELL (2015)
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
Gatien Moriceau et al.
CANCER CELL (2015)
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Tao Wang et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
Hojabr Kakavand et al.
CLINICAL CANCER RESEARCH (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
Michael Krauthammer et al.
NATURE GENETICS (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FOXP3+T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor
Connull Leslie et al.
PATHOLOGY (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
Sherille D. Bradley et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma
B. Schilling et al.
ANNALS OF ONCOLOGY (2014)
Management of melanoma
Pippa Corrie et al.
BRITISH MEDICAL BULLETIN (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Ping-Chih Ho et al.
CANCER RESEARCH (2014)
Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment
James S. Wilmott et al.
JOURNAL OF IMMUNOLOGY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα
Michael P. Smith et al.
CANCER DISCOVERY (2014)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Margaret K. Callahan et al.
CANCER IMMUNOLOGY RESEARCH (2014)
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
Laura J. Vella et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
Patrick A. Ott et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Immunological consequences of selective BRAF inhibitors in malignant melanoma Neutralization of myeloid-derived suppressor cells
Bastian Schilling et al.
ONCOIMMUNOLOGY (2013)
Mitogen-activated protein kinases in innate immunity
J. Simon C. Arthur et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
Mizue Terai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Genetic alterations of PTEN in human melanoma
Almass-Houd Aguissa-Toure et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mechanisms of Resistance to RAF Inhibitors in Melanoma
Andrew E. Aplin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
M. Sensi et al.
ONCOGENE (2006)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
分享论文
